img
img
Correlation of PD-L1 expression with immunohistochemically determined molecular profile in endometrial carcinomas   
Yazarlar (5)
Gozde Kir
Tuce Soylemez
Zeynep Cagla Olgun
Prof. Dr. Abdullah AYDIN Prof. Dr. Abdullah AYDIN
Kırşehir Ahi Evran Üniversitesi, Türkiye
W. Glenn McCluggage
Devamını Göster
Özet
Endometrial carcinoma programmed death-ligand 1 (PD-L1) expression in tumor cells (TCs) and tumor-associated inflammatory cells (ICs) have recently been reported in several studies which vary in terms of their cohort size, design, and methodology. We aimed to assess PD-L1 staining in endometrial carcinomas and correlate this with clinical and pathological factors and PTEN, ARID1A, p53, and MMR protein expression. PD-L1 immunohistochemistry was performed on whole tissue sections of all tumor blocks of 59 consecutive unselected endometrial carcinomas between November 2018 and September 2019. TC and IC PD-L1 positivity with a 1% cut-off value was observed in 10.2% and 67.8% of cases, respectively, and with a 5% cut-off value in 3.4% and 42.4% of cases, respectively. TC PD-L1 positivity with both 1% and 5% cut-off values was significantly related to ARID1A loss (p = 0.001 and p = 0.046, respectively). IC PD-L1 positivity with 1% and 5% cut-off values and combined score were significantly associated with MMR protein deficiency (p = 0.041, p = 0.031, and p = 0.028, respectively). Advanced stage tumors exhibited more frequent PD-L1 expression in ICs (p = 0.039). MELF-type myometrial invasion pattern was more common in tumors with ARID1A loss (p = 0.047). We observed higher rates of IC PD-L1 positivity in endometrial carcinomas than documented in prior studies; this may be related to our usage of "recent" paraffin blocks and whole tissue sections of all tumor blocks. There was a much higher PD-L1 expression in the ICs compared to TCs in our cases. We confirm a previously documented association between MMR deficiency and PD-L1 expression and show a novel association between ARID1A loss and PD-L1 expression in endometrial carcinomas. ARID1A loss represents a potential biomarker of immune checkpoint inhibitor response in endometrial carcinoma.
Anahtar Kelimeler
Endometrial carcinoma | Immunohistochemistry | MMR | ARID1A | PTEN | PD-L1
Makale Türü Özgün Makale
Makale Alt Türü ESCI dergilerinde yayımlanan tam makale
Dergi Adı VIRCHOWS ARCHIV
Dergi ISSN 0945-6317 Wos Dergi Scopus Dergi
Makale Dili İngilizce
Basım Tarihi 12-2020
Cilt No 477
Sayı 6
Sayfalar 845 / 856
Doi Numarası 10.1007/s00428-020-02867-9